Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Anti-chemokine small molecule drugs: a promising future?

Authors
Type
Published Article
Journal
Expert Opinion on Investigational Drugs
1744-7658
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
19
Issue
3
Pages
345–355
Identifiers
DOI: 10.1517/13543780903535867
PMID: 20113217
Source
Medline
License
Unknown

Abstract

In 2007, the FDA approved maraviroc, an inhibitor of CCR5 for the prevention of HIV infection, the first triumph for a small-molecule drug acting on the chemokine system. The time to market, 11 years from discovery of CCR5, was fast by industry standards. A second small-molecule drug, a CXCR4 antagonist for hematopoietic stem cell mobilization, was approved by the FDA at the end of 2008. The results of a Phase III trial with a CCR9 inhibitor for Crohn's disease are also promising. This could herald the first success for a chemokine receptor antagonist as an anti-inflammatory therapeutic and confirms the importance of chemokine receptors as a target class for anti-inflammatory and autoimmune diseases.

Statistics

Seen <100 times